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Introduction
Rapid receptor phosphorylation in response to agonist stimula-
tion is a posttranslational modifi  cation adopted by nearly all 
G protein–coupled receptors (GPCRs; Pierce et al., 2002). This 
event is generally accepted to be mediated by the GPCR kinase 
(GRK) family in a process that results in the recruitment of 
arrestin adaptor proteins to the receptor and the concomitant 
uncoupling of the receptor from its cognate G protein (Pierce 
et al., 2002). In addition, GRK phosphorylation can promote 
receptor activation of G protein–independent pathways such as 
the MAPK cascade (Wei et al., 2003).
This universal adaptive paradigm belies the complex na-
ture of GPCR phosphorylation and regulation. There are >340 
nonolfactory GPCR subtypes in the mammalian genome 
(Vassilatis et al., 2003) showing widespread tissue distribution 
and infl  uencing nearly every biological process from sensory 
perception to cell growth and differentiation (Wettschureck and 
Offermanns, 2005). Many of these receptors are phosphorylated 
at multiple serine, threonine (Blaukat et al., 2001; Pollok-Kopp 
et al., 2003; Trester-Zedlitz et al., 2005), and occasionally tyro-
sine residues (Fan et al., 2001). This multisite phosphorylation 
has been reported in some instances to be hierarchical and me-
diated by more than one protein kinase (Rao et al., 1997; Kouhen 
et al., 2000; Blaukat et al., 2001). Most enlightening have been 
studies on GRK knockout animals that have suggested that the 
same receptor subtype expressed in different tissues may be 
phosphorylated by a different complement of receptor kinases 
(Walker et al., 2004).
It is also the case that many receptor subtypes are found in 
more than one tissue type (Vassilatis et al., 2003) and mediate 
very specialized tissue-specifi  c responses. For example, the M3-
muscarinic receptor regulates membrane excitability in neurons 
(Millar et al., 2000), contraction and cell growth in smooth 
muscle cells (Gautam et al., 2005), and secretary vesicle priming 
and fusion in salivary acinar cells (Yoshimura et al., 2002; Gautam 
et al., 2005). It would appear intuitive that receptors expressed 
in different cell types, controlling specifi  c cellular responses, 
would be regulated in a manner specifi  c to that cell type.
Hence, a tantalizing alternative model of GPCR regulation 
is that phosphorylation is a fl  exible process of receptor modifi  ca-
tion where tissue-specifi  c differences in phosphorylation would 
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e demonstrate a role for protein kinase casein 
kinase 2 (CK2) in the phosphorylation and 
regulation of the M3-muscarinic receptor in 
transfected cells and cerebellar granule neurons. On ago-
nist occupation, speciﬁ   c subsets of receptor phospho-
acceptor sites (which include the SASSDEED motif in the 
third intracellular loop) are phosphorylated by CK2. 
Receptor phosphorylation mediated by CK2 speciﬁ  cally 
regulates receptor coupling to the Jun-kinase pathway. 
Importantly, other phosphorylation-dependent receptor 
processes are regulated by kinases distinct from CK2. 
We conclude that G protein–coupled receptors (GPCRs) 
can be phosphorylated in an agonist-dependent fashion 
by protein kinases from a diverse range of kinase families, 
not just the GPCR kinases, and that receptor phosphoryla-
tion by a deﬁ  ned kinase determines a speciﬁ  c signalling 
outcome. Furthermore, we demonstrate that the M3-
muscarinic receptor can be differentially phosphorylated 
in different cell types, indicating that phosphorylation is a 
ﬂ  exible regulatory process where the sites that are phos-
phorylated, and hence the signalling outcome, are depen-
dent on the cell type in which the receptor is expressed.
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underlie defined physiological functions. In this paradigm, 
differential deployment of receptor kinases in a tissue-  selective 
manner would result in differential phosphorylation that 
would facilitate the specifi  c physiological role of that receptor 
in a particular cell type.
Our work on the Gq/11-coupled M3-muscarinic receptor 
has demonstrated that this receptor subtype can be phosphory-
lated in an agonist-dependent manner by casein kinase 1α 
(CK1α), and this process regulates the coupling of the receptor 
to the extracellular-regulated kinase (ERK) 1/2 pathway (Budd 
et al., 2000, 2001; Tobin, 2002). These studies established that 
agonist-dependent GPCR phosphorylation could be mediated 
by protein kinases other than the GRKs (Tobin, 2002). In the 
current study, we extend our investigation of the CKs in GPCR 
phosphorylation and provide evidence that protein kinase CK2 can 
also phosphorylate the M3-muscarinic receptor. Furthermore, we 
show that the M3-muscarinic receptor is differentially 
phosphorylated in different cell types and that the action of spe-
cifi  c receptor kinases can determine the signaling outcome of 
receptor phosphorylation.
Results
Inhibition of CK2 decreases M3-muscarinic 
receptor phosphorylation
To investigate the role of the CK2 in M3-muscarinic receptor 
phosphorylation, we raised siRNAs against the catalytic α and 
α′ subunits of CK2. The effectiveness of the siRNAs was es-
tablished by cotransfection of the duplexes with plasmids ex-
pressing HA-tagged α or α′ subunits. In these experiments, we 
estimated the transfection effi  ciency of fl  uorescently labeled 
siRNAs to be  90% (unpublished data). The siRNAs desig-
nated CK2α-4 and CK2α′-1p effectively inhibited expression 
of the α and α′ subunits, respectively (Fig. 1 A). Furthermore, 
these siRNAs were active against the endogenously expressed 
kinase where the levels of the CK2α subunit fell by >85% with 
no subsequent change in the levels of CK1α, GRK2, GRK3, or 
GRK6 (Fig. 1 B). This corresponded to a fall in CK2 enzymatic 
activity of 68% compared with control (Fig. 1 C).
When used in phosphorylation experiments where the 
M3-muscarinic receptor was immunoprecipitated from CHO-
M3 cells labeled with [
32P]-orthophosphate, the CK2 siRNA 
duplexes reduced agonist-mediated M3-muscarinic receptor 
phosphorylation by  72% compared with scrambled siRNA 
controls (Fig. 1, D and E). These results were confi  rmed by 
raising further siRNA duplexes to different regions of 
CK2α and -α′ (Figs. S1 and S2, available at http://www.jcb
.org/cgi/content/full/jcb.200610018/DC1).
The third intracellular loop of the M3-muscarinic receptor 
is a serine-rich region containing several consensus sites for 
CK1α, CK2, and the GRKs, many of which are shared between 
these acidotropic kinases (Fig. 2 A). The ability of these kinases 
to phosphorylate the third intracellular loop is illustrated in 
Fig. 2 B, where GRK6 was found to phosphorylate the GST-fusion 
protein containing the third intracellular loop of the human 
M3-muscarinic receptor (R
253-T
492, called here GST-H3iloop) with 
the highest effi  ciency followed by CK1α and then GRK2 and 
CK2 (Fig. 2 B). None of the kinases phosphorylated GST alone 
(unpublished data).
To confi  rm of a role for CK2 in the phosphorylation of 
the M3-muscarinic receptor, the CK2-specifi  c pharmacological 
inhibitors 4,5,6,7-tetrabromo-1H-benzotriazole (TBB) and 
2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT; 
Pagano et al., 2004; Sarno et al., 2005) were used. The selec-
tively of these inhibitors was confi  rmed in assays using the fu-
sion protein GST-H3iloop as a substrate for CK1, CK2, GRK2, 
and GRK6 (Fig. 2 C). TBB at a concentration of 1 μM was very 
potent against CK2, reducing the level of GST-H3iloop by 
 75% but had only a small effect on CK1, GRK2, and GRK6 
(Fig. 2 C). DMAT also strongly inhibited CK2 with no signifi  cant 
effect on CK1 or GRK2 but was able to inhibit GRK6 by  45% 
(Fig. 2 C). These in vitro experiments were consistent with the re-
ported selectivity of the CK2 inhibitors and established that they 
Figure 1.  CK2 siRNAs decrease agonist-driven M3-muscarinic receptor 
phosphorylation. (A) Western blot analysis (using anti-HA antibody) of 
transfected HA-CK2α′ (left) and HA-CK2α (right) expression in CHO cells 
cotransfected with the indicated siRNA duplexes. α-Tubulin was used as a 
loading control. NT, nontransfected. (B) CHO cells were transfected with 
the indicated siRNAs and used to determine expression levels of endoge-
nous CK2α subunit, GRK2, GRK3, GRK6, and CK1α by immunoblotting 
with the indicated antibodies. (C) CK2 kinase activity in lysates from the 
siRNA transfected CHO cells was determined by the phosphorylation of 
a substrate peptide. Data correspond to mean ± SD from three indepen-
dent experiments. (D) Phosphorylation of the M3 receptor in CHO-M3 cells 
transfected with siRNA duplexes CK2α-4 and CK2α′-1p or scrambled con-
trol siRNAs (CNT) and stimulated with 100 μM methacholine for 5 min. 
(E) Quantitative analysis of phosphorylation from D. Phosphate content of 
M3 receptor was normalized to the basal level of phosphorylation. Data 
correspond to mean ± SD from three independent experiments.CK2 IN M3-RECEPTOR PHOSPHORYLATION • TORRECILLA ET AL. 129
can discriminate between the putative receptor kinases responsible 
for M3-muscarinic receptor phosphorylation.
The CK2 inhibitors were then used on intact CHO-M3 
cells to determine their effects on M3-muscarinic receptor 
phosphor  ylation. Both TBB and DMAT substantially reduced 
agonist-mediated phosphorylation of the M3-muscarinic recep-
tor by 76 and 58%, respectively (Fig. 2 D). These data are con-
sistent with the aforementioned siRNA experiments and 
demonstrate a role for CK2 in the phosphorylation of M3-
 muscarinic  receptors.
To further investigate the ability of CK2 to directly phos-
phorylate the M3-muscarinic receptor, membranes prepared 
from CHO-M3 cells that express recombinant human receptor 
were reconstituted with purifi  ed CK2. We noted previously that 
these membranes maintain the ability to phosphorylate the 
M3-muscarinic receptor (Tobin et al., 1993, 1996); hence, to 
reduce the endogenous kinase activity, the membranes were 
washed with 200 mM NaCl. Purifi  ed CK2 added to these mem-
branes resulted in an increase in receptor phosphorylation, al-
though this was not agonist regulated (Fig. 2 E).
M3-muscarinic receptor phosphorylation 
in cerebellar granule (CG) neurons
To test whether CK2 had a role in the phosphorylation of the 
M3-muscarinic receptor in a native cell type, we investigated 
mouse CG neuronal cultures where this receptor subtype is en-
dogenously expressed (Fohrman et al., 1993). To facilitate these 
studies, we raised an antibody against the region S
344-L
462 in the 
third intracellular loop of the mouse receptor that specifi  cally 
immunoprecipitated the mouse M3-muscarinic receptor when 
tested against all fi  ve muscarinic receptor subtypes (Fig. 3 A).
This antibody was subsequently used in phosphorylation 
experiments where 7-d-old mouse CG neurons were metaboli-
cally labeled with [
32P]-orthophosphate and stimulated with 
methacholine before being solubilized and the receptor immuno-
precipitated. In CG neurons from wild-type mice, the M3-
muscarinic receptor appeared as a  95-kD phosphoprotein that 
increased in the level of phosphorylation after agonist stimula-
tion in a manner that was inhibited by the muscarinic receptor 
antagonist atropine (Fig. 3 B). In CG neurons obtained from 
transgenic mice where the M3-muscarinic receptor gene had 
Figure 2.  Pharmacological inhibition of CK2 decreases agonist-mediated M3-muscarinic receptor phosphorylation. (A) The third intracellular loop of the 
M3-muscarinic showing the consensus sites for CK1α, CK2, and the GRKs as predicted using GPS (http://973-proteinweb.ustc.edu.cn/gps/gps_web/; 
Xue et al., 2005). (B) In vitro phosphorylation of a GST-H3iloop fusion protein by CK1, CK2, GRK2, and GRK6. The position of the fusion protein as de-
termined by Coomassie staining is shown. (C) In vitro phosphorylation of a GST-H3iloop fusion protein by CK1, CK2, GRK2, and GRK6 in the presence 
of 1 μM TBB and DMAT (CK2 inhibitors). Results are expressed as a percentage of controls (phosphorylation without the inhibitor). (D) M3-muscarinic re-
ceptor phosphorylation in CHO-M3 cells in the absence (control) or presence of TBB and DMAT (20 μM, 1.5 h). Cells were stimulated with 100 μM 
methacholine for 5 min. The inset shows representative autoradiographs. Quantiﬁ  cation of three independent experiments was normalized to the basal 
phosphorylation of control cells. Bars represent mean ± SD of at least three replicates. (E) Phosphorylation of the M3-muscarinic receptor contained in 
membrane preparations from CHO-M3 cells (or as a control CHO cells) in the presence and absence of CK2 and 0.1 mM methacholine. After a 10-min 
phosphorylation reaction, membranes were solubilized and the M3-muscarinic receptor was immunoprecipitated. The results shown are representative of 
three independent experiments. JCB • VOLUME 177 • NUMBER 1 • 2007  130
been knocked out (Yamada et al., 2001), this  95-kD receptor 
band was absent (Fig. 3 B).
To determine a role of CK2 in this phosphorylation event, 
the effect of the inhibitors TBB and DMAT on agonist-mediated 
receptor phosphorylation in CG neurons was investigated. Both 
TBB and DMAT reduced agonist-mediated phosphorylation 
from control levels of 2.47- ± 0.89-fold and 2.97- ± 0.06-fold 
over basal to 0.88- ± 0.37-fold and 0.98- ± 0.11-fold over 
basal, respectively (Fig. 3, C and D).
CK2 directs phosphorylation of a subset 
of sites in the intact M3-muscarinic receptor
Chymotryptic phosphopeptide maps were prepared from the 
receptor immunoprecipitated from CHO-M3 cells under condi-
tions where CK2 had been inhibited by siRNA knockdown 
(using CK2α-4/CK2α′-1p) or by pharmacological inhibition 
(with TBB). In these experiments (as before), quantifi  cation of 
receptor numbers by radioligand binding ensured that the same 
number of receptors had been immunoprecipitated from each 
sample. These maps revealed that CK2 siRNA and TBB inhib-
ited the phosphorylation of the same subset of phosphopeptides 
(Fig. 4, arrows and asterisks) while minimally affecting the phos-
phorylation of other phosphopeptides (Fig. 4).
SASSDEED motif in the third intracellular 
loop is a CK2 phosphoacceptor site
The sites of CK2-mediated receptor phosphorylation were in-
vestigated by two-dimensional chymotryptic phosphopeptide 
mapping. We established previously that the M3-muscarinic 
receptor is phosphorylated on serines in the third intracellular 
loop of the receptor (Budd et al., 2003). Here, we compared the 
chymotryptic phosphopeptide map of the receptor phosphory-
lated in a cellular context by endogenous kinases in CHO-M3 
cells with the map of a bacterial fusion protein containing the 
third intracellular loop of the M3-muscarinic receptor (GST-
H3iloop) phosphorylated in vitro by CK2. We know from pre-
liminary studies that this fusion protein is phosphorylated by 
CK2 in the muscarinic receptor portion only.
The phosphopeptide map obtained from the phos-
phorylated M3-muscarinic receptor, immunoprecipitated from 
[
32P]-orthophosphate–labeled CHO-M3 cells, was complex, with 
at least 19 distinct phosphopeptides identifi  ed (Fig. 5 A, right). 
In contrast, the phosphopeptide map from the in vitro phosphory-
lated GST-H3iloop demonstrated just fi  ve major phosphopep-
tides (Fig. 5 A, left). Four of these phosphopeptides migrated to 
very similar positions to phosphopeptides in the in vivo map, 
suggesting that they may represent the same phosphopeptides 
(Fig. 5 A, asterisks). It is also of interest that the peptides that 
are shown to decrease in the level of phosphorylation in CK2 
siRNA–treated cells (Fig. 4 A, arrows) closely correlated with 
peptides seen to be phosphorylated in vitro by CK2 (Fig. 5 A).
Edman degradation of peptide 1 in Fig. 5 A determined 
that it was phosphorylated in position 6 in both the in vitro sample 
Figure 3.  Pharmacological inhibition of CK2 decreases phosphorylation 
of the M3-muscarinic receptor in mouse CG neurons. (A) Immunoprecipita-
tion of biotinylated mouse M1–M5 muscarinic receptors using an in-house 
anti-mouse M3 antibody. Equal amounts of receptors in each lane were 
ensured by parallel [
3H]-NMS binding assays. (B) Phosphorylation of the 
M3-muscarinic receptor in CG neurons from wild-type and M3-knockout (K/O) 
mice. Neurons were metabolically labeled with [
32P]-orthophosphate and 
stimulated with 100 μM methacholine for 5 min in the presence or absence 
of 20 μM atropine as indicated. (C) Phosphorylation assays in CG neu-
rons treated with 10 μM TBB for 30 min or 20 μM DMAT for 15 min and 
stimulated with 100 μM methacholine for 5 min. The inset shows represen-
tative autoradiographs. Phosphorylation of the M3-receptor was quantiﬁ  ed 
and normalized to the basal phosphorylation of the receptor in control cells 
without inhibitor. Data represent mean ± SD of at least three replicates.
Figure 4.  CK2 inhibition decreases agonist-induced phosphorylation of 
only a subset of phosphoacceptor sites in the M3-muscarinic receptor. 
(A) Chymotryptic phosphopeptide maps of the M3-muscarinic receptor 
immunoprecipitated from CHO-M3 cells that had been transfected with 
scrambled control or CK2 siRNAs (CK2α-4/CK2α′-1p) and stimulated with 
100 μM methacholine for 5 min. Indicated are the origins of sample applica-
tion, direction of electrophoresis, and chromatography. Spots marked by 
the arrowheads and asterisks are those that increase in phosphorylation in 
control-stimulated cells but not in CK2 siRNA–treated cells. The arrows further 
represent spots that are in common with the in vitro CK2 phosphopeptide 
map shown in Fig. 5 A. (B) Same as A, but 20 μM TBB (1.5 h) was used 
to inhibit CK2 activity. Data is representative of at least three experiments.CK2 IN M3-RECEPTOR PHOSPHORYLATION • TORRECILLA ET AL. 131
and in vivo sample (Fig. 5 B). Similarly, for peptide 2, the major 
phosphoacceptor site was at position 15 in the in vitro and in 
vivo sample (Fig. 5 B). Thus, the fact that peptides 1 and 2 run 
in very similar positions in the phosphopeptide maps from the 
in vivo and in vitro samples and that these peptides are phos-
phorylated at the same position (residue) indicated that they are 
the same phosphopeptide phosphorylated in vitro by CK2 and 
in vivo by endogenous receptor kinases.
The occurrence of a phosphorylated serine at position 15 in 
spot 2 corresponded with a predicted chymotryptic peptide where 
the third intracellular loop serine 351 (S
351) was the 15th serine 
(Fig. 5 B). This serine is in the motif SASS
351DEED,  which 
is a classical CK2 consensus site (S-x-x-D/E/pS; Meggio and 
Pinna, 2003). Generation of a bacterial fusion protein 3iloop con-
struct where the SASSDEED motif was mutated to AAAADEED 
resulted a fusion protein that was phosphorylated predominantly 
at just two sites (Fig. 5 C, marked A and B) compared with the 
multisite phosphorylation seen in the wide-type fusion protein. 
In contrast, the sites phosphorylated by CK1 were not changed 
in the AAAADEED mutant (Fig. 5 C). These data indicate that 
the SASSDEED motif was not only a phosphoacceptor site for 
CK2 but that phosphorylation at this motif promoted further 
subsequent “hierarchal” phosphorylation events, a feature that is 
typical of CK2-mediated phosphorylation.
Similar analysis on spot 1, where residue 6 is phosphory-
lated, indicated that the potential phosphoacceptor sites could 
be contained in one of two predicted chymotryptic peptides, 
which start with the following sequences: VHPTGS
286SRS and 
ELQQQS
299MKRS. In the fi  rst of these sequences, the serine in 
position 6 fi  ts a consensus CK2 site only if position 9 is primed 
by phosphorylation. In the second peptide, the serine in position 6 
does not fi  t precisely into a consensus CK2 site, although prim-
ing by phosphorylation at position 10 might be suffi  cient. How-
ever, there is no evidence from the Edman degradation data 
presented here that priming at these sites occurs. Nevertheless, 
CK2 might be mediating phosphorylation at these sites (even in 
the absence of priming), a possibility that is currently being 
tested using mutants lacking these sites.
Phosphorylation of the third intracellular 
loop by GRK2, GRK6, and CK2
As illustrated in Fig. 2 A, the predicted sites at which the GRKs 
and CK2 might phosphorylate the receptor show some overlap. 
To investigate whether phosphoacceptor sites between CK2 and 
the GRKs were in fact shared, we generated chymotryptic 
phosphopeptide maps of GST-H3iloop phosphorylated with 
GRK2 and GRK6 and compared these to maps generated after 
the phosphorylation with CK2. The phosphorylation of the third 
intracellular loop protein by GRK2 and GRK6 appeared to occur 
at very similar sites, as determined by the fact that the phospho-
peptides migrated to similar positions and were phosphorylated 
on the same residues (i.e., spot A in GRK2 and GRK6 migrate 
to the same position and are both phosphorylated on residue 12; 
Fig. 6). In contrast, CK2 phosphorylated the receptor on very 
different sites, as determined by the different migration of phospho-
peptides. In the single peptide that appeared to run in a position 
similar to that of the GRKs (i.e., spot 1 runs similarly to spot A; 
Fig. 6), Edman degradation demonstrated that this peptide was 
phosphorylated at a different residue (i.e., residue 6) compared 
with the residue phosphorylated by the GRKs (i.e., residue 12). 
These data indicate that CK2 phosphorylated the third intracel-
lular loop at sites different from the GRKs.
CK2-mediated receptor phosphorylation 
does not regulate receptor internalization
Internalization of GPCRs has long been associated with recep-
tor phosphorylation (Shenoy and Lefkowitz, 2003). We tested 
this link for the M3-muscarinic receptor by removing putative 
phosphoacceptor sites through mutation of 16 serines in the 
Figure 5.  CK2 phosphorylates the SASSDEED motif in the third intracellular 
loop of the M3-muscarinic receptor. (A) Chymotryptic phosphopeptide 
map of GST-H3iloop phosphorylated by CK2 in vitro (left) and of the 
M3-muscarinic receptor phosphorylated in vivo by endogenous kinases 
in CHO-M3 cells (right). Indicated are the origins of sample application, 
direction of electrophoresis, and chromatography. Asterisks point out phospho-
peptides that migrate to similar positions in both maps. Maps depicted 
are representative of at least three experiments. (B) Peptides 1 and 2 were 
subjected to Edman degradation, and the product of each cycle was spot-
ted onto ﬁ  lter paper and exposed to determine which cycle contained the 
phosphorylated residue. The sequence shown is a predicted receptor chymo-
tryptic peptide where the serine in position 15 is at a consensus CK2 
phosphorylation site. (C) Comparison of the chymotryptic phosphopeptide 
map of the wild-type third intracellular loop fusion protein (left) and a fusion 
protein where the SASSDEED motif was been mutated to AAAADEED 
(right; AAAA mutant). These fusion proteins were phosphorylated with either 
CK2 (top) or CK1 (bottom). A representative experiment of at least three 
determinations is shown. The data shown were performed in parallel.JCB • VOLUME 177 • NUMBER 1 • 2007  132
third intracellular loop (Budd et al., 2004). This mutant receptor, 
termed mutant-6, was expressed normally at the cell surface, 
as determined by radioligand binding (unpublished data) and 
by biotinylation of cell surface proteins followed by immuno-
precipitation of the biotinylated M3-muscarinic receptor (Fig. 7 A). 
Furthermore, these receptor-biotinylation experiments demon-
strated that immunoprecipitation of mutant-6 was as effi  cient as 
that of the wild-type receptor and that the effi  ciency of immuno-
precipitation was not altered by ligand stimulation (Fig. 7 A). 
In subsequent phosphorylation experiments, the ability of 
the mutant-6 receptor to be phosphorylated in response to 
agonist was demonstrated to have been almost completely 
removed (Fig. 7 B).
The loss of receptor phosphorylation in mutant-6 corre-
lated with a loss in the ability of the receptor to be internalized 
after prolonged treatment with agonist. As shown in Fig. 6 C, 
stimulation of CHO-M3 cells expressing the wild-type M3-
muscarinic receptor resulted in a decrease in cell surface receptor 
expression, as measured by radioligand binding using the non-
membrane permeable antagonist [
3H]-N-methylscopolamine 
(NMS). In contrast, stimulation of cells expressing mutant-6 did 
not result in any signifi  cant change in the cell surface expression 
of the receptor (Fig. 7 C). This was confi  rmed using immuno-
histochemistry, where staining for the wild-type receptor showed 
a plasma membrane localization before agonist treatment 
but a characteristic endosomal localization after treatment with 
agonist for 30 min (Fig. 7 D). This was not the case for cells 
expressing mutant-6, where the receptor remains at the cell 
surface after exposure to agonist (Fig. 7 D).
Despite the fact that these data support a role for receptor 
phosphorylation in the internalization of the M3-muscarinic 
receptor, inhibition of CK2-mediated receptor phosphorylation 
by siRNAs directed against CK2 (Fig. 7 E) or pharmacological 
inhibition using TBB (Fig. 7 F) did not signifi  cantly affect 
receptor internalization. It appears, therefore, that receptor 
phosphorylation mediated by CK2 is not involved in receptor 
internalization, but rather other kinases (presumably of the GRK 
family; Tsuga et al., 1998) are responsible for this process.
Role of CK2-mediated receptor 
phosphorylation in coupling 
to MAPK pathways
We tested the role of CK2-mediated receptor phosphorylation in 
the coupling of the M3-muscarinic receptor to the ERK1/2 and 
Jun-kinase pathways. Fig. 8 A shows that siRNA-directed ago-
nist CK2 had no effect on the ability of the receptor to activate 
ERK1/2. In contrast, the magnitude of the Jun-kinase response 
was signifi  cantly increased after inhibition of CK2-mediated 
receptor phosphorylation, with the maximal response being 
approximately twofold greater in cells transfected with siRNA 
against CK2 compared with control transfected cells (Fig. 8 B). 
Similarly, the onset of the Jun-kinase response is faster in cells 
transfected with CK2 siRNA, where a signifi  cant response was 
evident at 10 min of agonist stimulation compared with 15 min 
in cells transfected with control scrambled siRNA (Fig. 8 B). 
Importantly, the control Jun-kinase response to sorbitol was not 
affected by CK2 inhibition (unpublished data).
The M3-muscarinic receptor is differentially 
phosphorylated in different cell types
Our study indicates that CK2 is among several protein kinases 
involved in the phosphorylation of the M3-muscarinic, each able 
to mediate a different signaling outcome (i.e., internalization/
Jun-kinase). A natural extension of these fi  ndings would be to 
hypothesize that cell type–specifi  c  receptor  phosphorylation 
could contribute to tissue-specifi   c signaling of the receptor. 
A fi  rst step in testing this hypothesis would be to determine if the 
receptor is differentially phosphorylated in different cell types. 
Hence, we compared the tryptic phosphopeptide maps of 
agonist-stimulated mouse M3-muscarinic receptors derived from 
transfected CHO cells with that of maps derived from receptors 
expressed in mouse CG neurons.
As can be seen in Fig. 9, the receptor expressed in CHO 
cells was phosphorylated both basally and in response to ago-
nist on many more sites than the receptor expressed in CG 
neurons. By comparing the migration of the spots, it can be seen 
that several of these phosphopeptides are common in the receptor 
maps derived from the two cell types (Fig. 9 B, marked with 
numbers), indicating that certain receptor phosphoacceptor sites 
are conserved. However, some of these common sites are differ-
entially regulated by agonist. Hence, the phosphopeptide marked A 
Figure 6.  Comparison of the phosphorylation of GST-H3iloop with GRK2, 
GRK6, and CK2. The GST fusion protein containing the third intracellular 
loop of the human M3-muscarinic receptor (GST-H3iloop) was phosphory-
lated with GRK2, GRK6, or CK2, and chymotryptic phosphopeptide maps 
were generated. (A) Chymotryptic phosphopeptide maps resulting from 
GRK2, GRK6, or CK2 phosphorylation. (B) The phosphopeptides labeled 
A, B, and C from the GRK phosphorylations and the peptides labeled 1 
and 2 from the CK2 phosphorylation were subjected to Edman degrada-
tion, and the cycle in which radioactivity was detected is given. Note that 
the CK2 data is reproduced from Fig. 5 to enable easy comparison against 
the GRK phosphopeptide maps.CK2 IN M3-RECEPTOR PHOSPHORYLATION • TORRECILLA ET AL. 133
is agonist regulated in CG neurons but is constitutively phos-
phorylated in CHO cells. Furthermore, the peptide marked B 
is agonist regulated only in CHO cells (Fig. 9 A).
Although some of the phosphopeptides are common to the 
two cell types, others are cell type specifi  c. Five examples of 
phosphopeptides identifi  ed only in CHO-derived receptors are 
marked with open arrowheads in Fig. 9 B (left), and an example 
of a phosphopeptide specifi  c to CG neurons is marked with 
a closed arrowhead (right).
Discussion
Agonist occupation results in the multisite phosphorylation of 
GPCRs by receptor kinases in a manner often described as ho-
mologous phosphorylation. There is now a large body of evi-
dence to support the role of the GRK family in this process 
(Pierce et al., 2002). However, it is clear from studies using 
phosphoacceptor site mutants (Seibold et al., 2000), peptide 
mapping (Blaukat et al., 2001), mass spectrometry (Trester-
Zedlitz et al., 2005), phosphospecifi  c antibodies (Pollok-Kopp 
et al., 2003; Tran et al., 2004), and transgenic animals (Walker 
et al., 2004) that the process of receptor phosphorylation is 
complex, suggesting the possibility of the involvement of pro-
tein kinases in addition to the GRKs (Tobin, 2002).
By use of CK2 inhibitors and siRNA against the α and α′ 
catalytic subunits of CK2, we demonstrate that CK2 contributes 
to the phosphorylation of the M3-muscarinic receptor in both a 
heterologous expression system and in mouse neurons. Further-
more, by using phosphopeptide maps, we show that in vitro phos-
phorylation of the third intracellular loop of the M3-muscarinic 
receptor by CK2 results in the phosphorylation of sites that are 
also phosphorylated by endogenous kinases in vivo. Impor-
tantly, these in vivo sites are seen to decrease in phosphoryla-
tion after CK2 siRNA treatment. Finally, we show that purifi  ed 
CK2 can increase the phosphorylation state of the intact M3-
muscarinic receptor in membranes prepared from CHO-M3 
cells. Thus, CK2 can be added to GRK2, GRK6, and CK1α as 
a protein kinase that can phosphorylate the M3-muscarinic re-
ceptor in an agonist-dependent manner (Budd et al., 2000; Wu 
et al., 2000; Willets et al., 2003).
What might be the signifi  cance of multikinase receptor 
phosphorylation? Despite CK1α and CK2 sharing the same 
nomenclature, they are structurally distinct protein kinases, a fact 
highlighted in Hanks and Hunter’s (1995) classifi  cation, where 
CK2 is classifi  ed as a CMGC kinase and CK1α as a member of 
the CK1 family. This compares with the GRKs that are classifi  ed 
as ACG kinases. It appears, therefore, that the M3-muscarinic 
receptor can be phosphorylated in an agonist-dependent manner 
Figure 7.  Internalization of the M3-muscarinic 
receptor is dependent on non–CK2-mediated 
receptor phosphorylation. (A) Immunoprecipi-
tation of biotinylated wild-type and mutant-6 
M3-muscarinic receptors from CHO cells. 
Equal quantities of receptor (as determined by 
[
3H]-NMS assay) were used in the immuno-
precipitation. NT, nontransfected cells. (B) Phos-
phorylation of wild-type and mutant-6 receptors 
in response to 100 μM methacholine for 
5 min. (C) Internalization of the M3-muscarinic 
receptor was determined by stimulation with 
100 μM methacholine for the times indicated 
followed by the quantiﬁ  cation of cell surface 
receptor expression using [
3H]-NMS binding 
at 4°C. The histograms represent the percent-
age binding and correspond to mean ± SD 
of  three experiments. Statistical comparison 
was performed using a one-way ANOVA with 
Bonferroni posttest. 
++, P < 0.001 between 
nonstimulated and methacholine treated cells; 
**, P < 0.001 between wild-type and mutant-6 
cells. (D) Representative experiment of the 
redistribution of M3 receptors in response to 
methacholine treatment. After stimulation, cells 
were ﬁ  xed and stained with the anti-M3 anti-
body followed by FITC ﬂ  uorescence analysis. 
Bars, 10 μm. (E) Internalization of the M3-
muscarinic receptor in CHO-M3 cells trans-
fected with scrambled control siRNA or CK2 
siRNA (CK2α-4/CK2α′-1p) as measured by 
[
3H]-NMS binding at 4°C. (F) Internalization of 
the M3-muscarinic receptor in CHO-M3 cells 
treated with 20 μM TBB for 1.5 h. Statistical 
comparison was performed using a one-way 
ANOVA with Bonferroni posttest. *, P > 0.05 
(no signiﬁ  cant difference between treated and 
nontreated cells).JCB • VOLUME 177 • NUMBER 1 • 2007  134
by protein kinases from very different families with distinct 
structural features, mechanisms of regulation and subcellular 
localization. This diversity would allow for a very fl  exible pro-
cess of receptor regulation, where not only can different sites on 
the receptor be phosphorylated by different protein kinases but 
also the differential mechanisms of activation and regulation of 
protein kinase activity/localization could infl  uence  receptor 
phosphorylation and signaling.
The fact that more than one structurally distinct protein 
kinase family has a role in M3-muscarinic receptor phosphoryla-
tion is refl  ected in the numerous phosphoacceptor sites deter-
mined from the proteolytic phosphopeptide maps conducted in 
this study. Furthermore, by comparing the in vitro CK2-mediated 
phosphopeptides with in vivo phosphopeptide maps, and by the 
analysis of phosphopeptide maps from cells where CK2 was in-
hibited using either siRNA or pharmacological inhibitors, we 
demonstrate that only a subset of the phosphoacceptor sites on 
the M3-muscarinic receptor are phosphorylated by CK2.
This data points to the fact that the distinct receptor ki-
nases for the M3-muscarinic receptor are able to phosphorylate 
defi  ned sites on the receptor. This is supported by comparisons 
of the phosphopeptide maps after the phosphorylation of the 
third intracellular loop by GRK2, GRK6, and CK2, which dem-
onstrated that CK2 can indeed phosphorylate sites different 
from those phosphorylated by the GRKs. In the case of CK2, 
we determined that one of these sites was the SASSDEED mo-
tif in the third intracellular loop. Phosphorylation at this motif 
promotes further CK2-mediated phosphorylation in a process 
akin to hierarchal phosphorylation, which is a common feature 
of this protein kinase.
The question that arises from these observations is whether 
phosphorylation by different receptor kinases can result in dif-
ferent signaling outcomes. We addressed this here by focusing 
on three signaling processes well known to be regulated by re-
ceptor phosphorylation, namely, receptor internalization, acti-
vation of the ERK1/2, and activation of the Jun-kinase pathway 
(Pierce et al., 2002). Our study showed that inhibition of CK2-
mediated phosphorylation does not affect receptor internal-
ization. This is the case despite the fact that M3-muscarinic 
receptor internalization is a phosphorylation-dependent pro-
cess. Thus, receptor internalization must be driven by a non–
CK2-dependent phosphorylation. Our unpublished data shows 
that CK1α inhibition similarly does not affect receptor internal-
ization. It appears most likely that M3-muscarinic receptors are 
internalized in a GRK-dependent manner, as has previously 
been reported for this receptor subtype (Tsuga et al., 1998).
Receptor coupling to the ERK1/2 pathway is similarly not 
affected by inhibition of CK2-mediated receptor phos-
phorylation. We have shown previously that this signaling response 
Figure 8.  CK2 regulates M3-muscarinic receptor activation of Jun-kinase 
but not ERK1/2. CHO-M3 cells treated with control scrambled or CK2 
siRNAs (CK2α-4/CK2α-1p) were stimulated with 100 μM methacholine 
for the indicated times, and cell extracts were obtained and used in an 
ERK1/2 kinase assay where the ERK substrate was an EGFr peptide (A) or 
a Jun-kinase assay where GST–c-Jun fusion protein was a substrate for Jun-
kinase (B). Phosphate incorporated into substrates GST–c-Jun or EGFr per 
milligram of protein in cell extracts was normalized to the basal level of 
phosphorylation (time 0). Data correspond to mean ± SD from at least 
three experiments. *, P < 0.05 (signiﬁ  cant difference between stimulated 
levels and control).
Figure 9. The  M3-muscarinic receptor is differentially phosphorylated in 
different cell types. (A) CHO cells expressing the mouse M3-muscarinic re-
ceptor (top) or CG neurons (bottom) were 
32P-labeled and treated with or 
without 100 μM methacholine for 5 min. The receptors were then immuno-
precipitated, and a tryptic phosphopeptide map was generated. These 
maps are representative of three CHO and two CG neurons replicates with 
very similar results. (B) Comparison of receptor tryptic phosphopeptides 
(phosphorylation signatures) from methacholine-stimulated CHO (left) and 
CG cells (right). These maps are the same as shown in A except that the 
numbered phosphopeptides indicate those that migrate to similar positions 
in both maps, whereas the open arrowheads represent phosphopeptides 
that are speciﬁ  c to CHO cells and the closed arrowhead a phosphopeptide 
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is likely to be regulated by CK1α (Budd et al., 2001). In contrast, 
we show here that CK2 activity is important in coupling the re-
ceptor to the Jun-kinase pathway. Inhibition of CK2 via siRNA 
substantially increases both the magnitude and time course of 
the Jun-kinase response to muscarinic receptor stimulation but 
has no affect on the receptor-independent activation of the Jun-
kinase pathway mediated by sorbitol. Because we show that 
CK2 is able to mediate receptor phosphorylation, our data point 
to the possibility that CK2-mediated receptor phosphorylation 
can regulate the coupling of the M3-muscarinic receptor to the 
Jun-kinase pathway and none of the other phosphorylation-
dependent signaling pathways. This supports the notion that 
site-specifi  c phosphorylation mediated by a single receptor 
kinase can regulate a defi  ned receptor signaling process. Our 
studies do not, however, completely rule out the possibility that 
CK2 has an indirect role on receptor coupling to the Jun-kinase 
pathway that is independent of receptor phosphorylation.
A logical extension of this fi  nding is that GPCR phos-
phorylation might be used as a fl  exible adaptive process where 
a defi  ned complement of protein kinases would be recruited to 
phosphorylate specifi  c sites in a process that would allow for 
 tissue-specifi  c signaling. Hence, in the case of the M3-muscarinic 
receptor, such a process would contribute to the very different 
physiological responses mediated by this receptor when ex-
pressed in smooth muscle cells compared with the same recep-
tor subtype expressed in salivary acinar cells and neurons.
In the current study, we tested whether the M3-muscarinic 
receptor was able to be phosphorylated in a cell type–specifi  c 
fashion by comparing the tryptic phosphopeptide maps obtained 
from the mouse M3-muscarinic receptor immunoprecipitated 
from CHO cells and mouse CG neurons. We refer to the pat-
tern obtained from these maps as phosphorylation signatures. 
By comparing the receptor phosphorylation signatures obtained 
in CHO cells and CG neurons, it was clear that some elements 
of receptor phosphorylation were the same between the two 
cell types, whereas others were cell type specifi  c. The common 
features of these maps may underlie common regulatory pro-
cesses, such as receptor internalization, whereas those phos-
phorylation events that are unique to a given cell type might be 
involved in cell type–specifi  c signaling. It was clear from these 
studies that at least between these two cell types the phosphory-
lation signatures of the M3-muscarinic receptors were different, 
indicating that differential cell type–specifi  c phosphorylation 
indeed occurs. Our continuing studies aimed at defi  ning the 
role of these cell type–specifi  c phosphorylation events in physi-
ologically relevant tissues will test further whether this differ-
ential phosphorylation pattern is related to cell type–specifi  c 
functional responses.
Materials and methods
Primary cell culture
Mouse CG neurons were cultured as described previously (Leist et al., 
1997). In brief, cerebella from 7–8-d-old BALB/c or transgenic pups were 
mechanically and enzymatically (trypsin) dissociated and plated at 0.25 × 
10
6 cells/cm
2 on 100 μg/ml poly-L-lysine–coated 6- or 12-well plates 
(Nunc). CG neurons were then incubated in Eagle’s basal medium supple-
mented with 20 mM KCl, penicillin/streptomycin, 10% fetal calf serum, 
and 10 μM cytosine arabinoside (added 48 h after plating) in a humidi-
ﬁ  ed atmosphere with 5% CO2 at 37°C for 7–8 d.
siRNAs
siRNAs were chemically synthesized (Ambion). The siRNA sequences tar-
geting CK2 were CK2α-4, 5′-AacaUUgaaUUagaUccacgU-3′; and CK2α′-
1p, 5′-AagaUUcUggagaaccUUcgU-3′. These siRNAs targeted to sequences 
that are 100% conserved between rat, mouse, and human CKs.
Scrambled siRNA of CK2α-4 and CK2α-1p were used as nonsilencing 
controls. Transient transfections of siRNA duplexes were performed in 80% 
conﬂ  uent CHO cells in 6- or 12-well plates using 120 nM siRNA and 3 μl 
si-PORTamine transfection reagent (Ambion) according to the manufacturer’s 
protocol. Cells were used for experiments after 48 h.
M3-muscarinic receptor phosphorylation and phosphopeptide mapping
The phosphorylated M3-muscarinic receptor was immunoprecipitated from 
50  μCi/ml [
32P]-orthophosphate–labeled cells as previously described 
(Budd et al., 2004). Equivalent amounts of immunoprecipitated receptor in 
each sample were ensured by parallel radiolabeled ligand binding experi-
ments using the antagonist [
3H]-NMS (Budd et al., 2004). The immuno-
precipitated receptor was resolved on 8% SDS-PAGE and visualized by 
autoradiography or using a phosphorimager (STORM; GE Healthcare).
In the case of CG cells, the procedure was the same, but CSS-25 in-
cubation buffer (120 mM NaCl, 1.8 mM CaCl2, 15 mM glucose, 25 mM 
KCl, and 25 mM Hepes, pH 7.4) containing 100 μCi/ml [
32P]-orthophos-
phate was used. The receptor was immunoprecipitated from cell lysates 
obtained by pooling 2 wells of a 6-well plate. In these experiments and 
others involving the mouse receptor, we used an in-house anti–mouse M3-
muscarinic receptor antibody (see Generation of mouse M3-muscarinic re-
ceptor antibody).
For phosphopeptide mapping, CHO-M3 cells and CG neurons were 
labeled with 100 or 200 μCi/ml [
32P]-orthophosphate, respectively. Stimu-
lation and immunoprecipitation were performed as described. The immuno-
precipitated samples of one entire 6-well plate of CHO cells or 2 plates of 
CG neurons were pooled and resolved by SDS-PAGE. The gel was then 
electroblotted onto nitrocellulose membrane, and the phosphorylated re-
ceptor was visualized by autoradiography. The area of the membrane con-
taining the receptor was cut out, blocked for 30 min at 37°C with 0.5% 
polyvinylpyrrolidone-K 30 (Sigma-Aldrich) containing 0.6% acetic acid, 
and washed several times with water. The M3-muscarinic receptor con-
tained on the membrane was digested for 20 h at 37°C in ambic solution 
(50 mM NH4HCO3 and 0.5 mM CaCl2) containing 10 μg/ml of either 
trypsin (Promega) or chymotrypsin (Sigma-Aldrich). The supernatant was 
then removed, and the membrane slice washed once with water. The wash 
and supernatant were combined dried. Tryptic/chymotryptic peptides 
were then resuspended in 10 μl pH 1.9 buffer (88% formic acid/acetic 
acid/water, 25:78:897 vol/vol) and spotted onto cellulose-coated chro-
matography (TLC) plates (20 × 20 cm; Merck). The peptides were then 
separated in two dimensions. The ﬁ  rst dimension was electrophoresis at 
2,000 V for 30 min in pH 1.9 buffer using a Hunter HTLE-7002 system 
(CBS Scientiﬁ  c). The second dimension was ascending chromatography in 
isobutyric buffer (isobutyric acid/n-butanol/pyridine/acetic acid/water, 
1,250:38:96:58:558 vol/vol). The resolved phosphopeptides were then 
visualized using a STORM phosphorimager.
In vitro phosphorylation of GST-H3iloop fusion protein
The human M3-muscarinic receptor third intercellular loop (R
253-T
492) cloned 
in-frame with GST (GST-H3iloop) was expressed and puriﬁ  ed from bacteria 
as previously described (Tobin and Nahorski, 1993). 35 μg of fusion pro-
tein bound to glutathione–Sepharose beads was incubated with 100 units 
of CK1 or CK2 (New England Biolabs, Inc.) or 100 ng of puriﬁ  ed GRK2 
(provided by R. Lefkowitz, Duke University Medical Center, Durham, NC) 
or GRK6 (provided by J. Tesmer, University of Michigan, Ann Arbor, MI) 
in kinase assay buffer (10 mM MgCl2, 20 mM β-glycerophosphate, and 
20 mM Hepes, pH 7.4) with 50 μM ATP and 10 μCi γ-[
32P]ATP in a total 
volume of 100 μl. The reaction was continued for 30 min at 37°C. To de-
termine the inhibition potency of TBB and DMAT (Calbiochem), protein ki-
nases were preincubated for 10 min in the same buffer without ATP and 
with 1 μM of each inhibitor. Reactions were stopped by the addition of 
1 ml of ice-cold buffer, and the GST-H3iloop:glutathione–Sepharose beads 
were pelleted and resuspended in 2× SDS-PAGE sample buffer before 
being resolved by SDS-PAGE. Quantiﬁ  cation of the phosphorylation status 
of GST-H3iloop was determined by phosphorimager analysis. Alternatively, 
the phosphorylated GST-H3iloop was blotted onto nitrocellulose membrane 
and used in phosphopeptide mapping as described.JCB • VOLUME 177 • NUMBER 1 • 2007  136
Phosphorylation of the M3-muscarinic receptor 
on membrane preparations
Crude membranes were prepared from CHO-M3 and CHO cells and 
stored at −80°C as described previously (Tobin et al., 1993). Before use, 
membranes were washed for 15 min with kinase buffer (25 mM Tris-HCl, 
pH 7.4, 20 mM β-glycerophosphate, 200 mM NaCl, 10 mM MgCl2, and 
100 μg/ml BSA). Membranes were then pelleted in a microfuge (3 min at 
21,000 g) and resuspended in kinase buffer before use in the in vitro 
phosphorylation reaction, which consisted of membranes (200 μg protein) 
and kinase buffer containing γ-[
32P]-ATP (2 μM; 1–4 disintegrations per 
minute/fmol) in the presence or absence of CK2 (200 or 500 units per 
reaction) in a reaction volume of 200 μl. Reactions were incubated at 37°C 
for 10 min. Reactions were stopped by pelting membranes in a microfuge 
(21,000 g for 1 min), and solubilization of the membrane pellet and immuno-
precipitation of the M3-muscarinic receptor were performed as described 
previously (Tobin et al., 1993).
Radioligand binding and internalization assays 
and immunohistochemistry
Expression of cell surface muscarinic receptors after exposure of cells 
to methacholine for the indicated times was determined as described 
previously (Budd et al., 1999) except that saturating concentrations 
(0.5 nM) of the muscarinic antagonist [
3H]-NMS was used in incubations 
with whole cells for 60 min at 37°C. Washes were then conducted at 4°C 
(Budd et al., 1999).
To determine subcellular localization of the M3-muscarinic receptor 
using immunohistochemistry, cells were ﬁ  xed with 4% paraformaldehyde 
and permeabilized with Triton X-100 and the receptor was stained using a 
1:500 dilution of an in-house anti-human M3-muscarinic receptor antibody 
(Tobin and Nahorski, 1993).
MAPK assays
Cells plated onto 6-well dishes were serum starved for 1 h and stimulated 
with 0.1 mM methacholine for the times indicated. The cells were then 
lysed, and cellular ERK1/2 was immunoprecipitated and assayed in an in 
vitro assay using the EGFr peptide substrate as described previously (Budd 
et al., 2001). Alternatively, Jun-kinase was isolated from the cell lysate us-
ing a GST–c-Jun fusion protein followed by the in vitro phosphorylation of 
GST–c-Jun as previously described (Budd et al., 2003).
Biotinylation
Cells cultured on 6-well plates were incubated in buffer containing 1 mM 
biotin (Pierce Chemical Co.) for 30 min at 37°C. The cells were then lysed, 
and the M3-muscarinic receptor was immunoprecipitated as described 
for phosphorylation experiments. Equivalent amounts of receptor were 
ensured by analysis of receptor levels using [
3H]-NMS radiolabeling. 
Samples were then separated by SDS-PAGE, electroblotted to nitrocellulose 
membranes, and, after blocking with TBST plus 5% milk powder for 1 h, 
incubated with 50 ng/ml streptavidin conjugated to horseradish peroxidase 
(Pierce Chemical Co.) for 30 min. Biotinylated proteins were then detected 
with chemiluminescence reagent (ECL plus; GE Healthcare).
Generation of mouse M3-muscarinic receptor antibody
The region S
344-L
462 of the mouse M3-muscarinic receptor third intracellular 
loop was produced as an N-terminal tagged GST/receptor fusion protein, 
which was used to inoculate New Zealand white rabbits (Harlan Sera-Labs). 
The resulting antisera was tested in immunoprecipitation studies and shown 
to speciﬁ  cally react with the mouse M3-muscarinic receptor (Fig. 3).
CK2 activity assay
48 h after siRNA transfection, CHO cells cultured in 12-well dishes were 
harvested in lysis buffer (25 mM Tris-HCl, pH 7.4, 20 mM β-glycerophos-
phate, and 200 mM NaCl) containing 0.5% NP-40 substitute (Fluka). 
The kinase assay (using 10 μl of cell lysate) was performed in lysis buffer 
containing 1 μM ATP, 10 mM MgCl2, 100 μg/ml BSA, 50 μM CK2 
peptide substrate R  R  R  E  E  E  T  E  E  E   (Promega), and 1 μCi γ-[
32P]ATP (total 
volume 50 μl). After a 15-min incubation at 37°C, half of the mixture 
was spotted on phosphocellulose P81 ﬁ  lter (Whatman) and washed four 
times with 0.5% H3PO4. The ﬁ   lters were then transferred to vials con-
taining scintillation ﬂ   uid (Safeﬂ   uor) and counted. The phosphorylation 
assays were performed in either the presence or absence of 1 μM of the 
CK2 inhibitor TBB. CK2 activity was then determined as the TBB-sensitive 
component of the peptide phosphorylation, which was  20% of the total 
peptide phosphorylation.
Data analysis
Autoradiography densitometric analysis was performed using ImageQuant 
and AlphaEase FC softwares. SD of at least three determinations is pre-
sented, and signiﬁ  cance was determined using a one-way analysis of 
variance (ANOVA).
Online supplemental material
Fig. S1 shows the sequences on CK2α and -α′ subunits that were targeted 
by siRNAs. These siRNAs were then tested for the ability to reduce expression 
of CK2 and effects on M3-muscarinic receptor phosphorylation (Fig. S2). 
This data demonstrated that siRNAs distinct from those used in Fig. 1 were 
also able to reduce CK2 expression, and this correlated with a reduction 
in receptor phosphorylation. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.200610018/DC1.
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